Attacking Rare Disease IgA Nephropathy at the Source in the Gut with Renee Agular-Lucander Calliditas Therapeutics

17:03
 
Share
 

Manage episode 295084133 series 99915
By Karen Jagoda. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Renee Agular-Lucander is CEO of Calliditas Therapeutics a Sweden-based clinical-stage biopharmaceutical company focused on the rare kidney disease IgA nephropathy. While there is a genetic predisposition for this autoimmune disease, it is still not clear what triggers the condition and there is no current cure.

Renee talks about:

  • Lead drug candidate Nefecon which starts at the top of the disease cascade in the ileum part of the small intestine. Delivering this disease-modifying agent directly interrupts and disrupts the beginning of the disease
  • How clinical trial data is showing the value of addressing the gut-renal axis and treating this indication in an organ-specific way
  • Other orphan indications that might benefit from this approach
  • What the FDA priority review of Nefecon potentially means for the 1 in every 4 adults with IgAN who will eventually succumb to kidney failure.

@Calliditas1 #IgANephropathy #IgAN #Kidney #KidneyDisease #EndStageRenalDisease #AutoimmuneDisease #Nefecon #RareDisease

Calliditas.se/en

Download the transcript here

677 episodes